<DOC>
	<DOCNO>NCT01417429</DOCNO>
	<brief_summary>This 2-4 week double-blind , placebo-controlled study . Twenty four male female smoker first two 4-day treatment period , randomize galantamine ( 8 mg/day ) placebo . These treatment period separate 3 14 day washout period . During first 3-days treatment period , smoker daily clinic visit , receive study medication adverse effect study medication monitor . Starting 10 p.m. Day 1 treatment period , subject refrain smoke approximately 2.5 day , experimental session Day 4 . Compliance non-smoking verify CO level &lt; 10 ppm . During experimental session , subject receive saline 1.0 mg/70 kg nicotine intravenously random , double-blind manner . The sequence nicotine treatment counterbalance among subject equal number subject receive saline first nicotine first . Following saline nicotine treatment , physiological , subjective cognitive measurement obtain</brief_summary>
	<brief_title>Galantamine Effects Nicotine Responses Smokers</brief_title>
	<detailed_description>In double-blind , crossover study , investigator propose evaluate galantamine 's effect subjective nicotine effect severity tobacco withdrawal symptom . Twenty four male female smoker first two 4-day treatment period , subject randomize galantamine ( 8 mg/day ) placebo . These treatment period separate 3 14 day washout period . This range washout period , minimize carryover medication effect treatment , provide flexibility subject comply study procedure . During study participation , subject instruct continue smoke usual study except 2.5 day smoke abstinence test session . Starting 10 p.m. Day 1 treatment period , subject refrain smoke approximately 2.5 day , test session Day 4 . Subjects twice daily outpatient visit first 3 day test session day 4 . During outpatient visit , study medication administer tobacco withdrawal symptom compliance smoke abstinence monitor . On Day 4 treatment phase subject test session , receive saline 1.0 mg/70 kg nicotine intravenously random , double-blind manner . The sequence nicotine treatment counterbalance among subject equal number subject receive saline first nicotine first . Following saline nicotine administration , physiological , subjective cognitive measurement obtain . Currently 12 subject complete protocol . This study data analysis . ( April 2011 )</detailed_description>
	<mesh_term>Nicotine</mesh_term>
	<mesh_term>Galantamine</mesh_term>
	<criteria>Inclusion criterion : female male smoker , age 18 55 year ; history smoke daily past 12 month , least 15 cigarette daily ; CO level &gt; 10ppm ; woman : pregnant determine pregnancy screening , breast feeding , use acceptable birth control method . Exclusion criterion : history major medical illness include asthma chronic obstructive lung disease , history current gastrointestinal ulcer , hepatic renal impairment cardiac rhythm disturbances medical condition study physician deems contraindicate subject study ; regular use psychotropic medication ( antidepressant , antipsychotic , anxiolytic ) and/or recent psychiatric diagnosis treatment Axis I disorder include major depression , bipolar affective disorder , schizophrenia panic disorder within past year ; current dependence alcohol drug treatment drug alcohol addiction ; use drug slow heart rate ( eg , betablockers ) , may increase risk bradycardia AV block , NSAIDs , may increase potential develop ulcers/active occult gastrointestinal bleeding ; know allergy galantamine</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>galantamine</keyword>
	<keyword>subjective nicotine</keyword>
	<keyword>tobacco withdrawal symptom</keyword>
	<keyword>nicotine</keyword>
</DOC>